Safety, Pharmacokinetics, and Antiviral Activity of the S-Antigen Transport Inhibiting Oligonucleotide Polymers (STOPSTM) Drug Candidate ALG-010133 in Subjects with Chronic Hepatitis B


1University of Auckland, New Zealand; 2Institute of Liver Studies, Kings College Hospital, United Kingdom; 3University of Hong Kong, Hong Kong; 4RENSSJA Exploratory Medical Research, Republican Clinical Hospital and Nicolaie Testemitanu State University of Medicine and Pharmacy, Moldova; 5New Zealand Clinical Research, New Zealand; 6Aligos Therapeutics Inc. United States; 7SARPO Consulting, Australia

INTRODUCTION

Worldwide, more than 296 million people are affected by Chronic Hepatitis B (CHB) and ~820,000 people per year die from cirrhosis and hepatocellular carcinoma (HCC) due to CHB.1 Long-term treatment with current standard of care for CHB, nucleoside (n) or nucleotide (NA) or pegylated interferon, suppresses HBV replication and reduces liver injury in most patients, but rarely results in functional cure, the goal of CHB treatment.2 Therefore, there is a significant medical need for novel approaches to enhance functional cure rates.

ALG-010133 is an S-Antigen Transport Inhibiting Oligonucleotide Polymer (STOPSTM) molecule which, in vitro, substantially reduces Hepatitis B surface antigen (HBsAg) production and release from infected hepatocytes with single digit nanomolar potency. ALG-010133 was being developed as a potential component of a finite duration combination regimen to achieve higher rates of functional cure. Study ALG-010133-101 (NCT04485663) was a 3-part, multicenter, double blind, randomized, placebo-controlled Phase 1 study designed to determine the preliminary safety, pharmacokinetics (PK) and antiviral activity of ALG-010133 in healthy volunteers (HVs) and CHB subjects. In Parts 1 and 2, single and multiple subcutaneous (SC) doses were generally well-tolerated in HVs. Part 3 data evaluating the drug in CHB subjects are presented here.

AIM

To evaluate the safety, PK, and antiviral activity of multiple SC doses of ALG-010133 in CHB subjects.

METHODS

• Subjects in Part 3 of Study ALG-010133-101 received 12 weekly SC doses of ALG-010133 or placebo. Each cohort consisted of 10 CHB subjects randomized 1:1 to ALG-010133 or placebo. Key eligibility criteria for Part 3 of this study were:
  • Virologically suppressed (VS) HBsAg <20 U/L
  • HBsAg positive
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2x upper limit of normal (ULN) and HBsAg ≥2 log10 (IU/mL) at screening
  • Metavir Score ≤2
  • Assessments of safety (adverse events [AEs], vital signs, electrocardiogram [ECG], physical examinations, and laboratory), viral kinetics (HBsAg, HBV DNA/RNA) and plasma/unnae PHK were systematically collected and analyzed.
  • Blood samples were assessed for ALG-010133 plasma concentrations using validated hybridization-based Assay-Exchange High Performance Liquid Chromatography (AEX-HPLC) method coupled to a fluorescence detector and/or LC-MS/MS method.

PHARMAKOKINETICS

Plasma ALG-010133 exposures increased more than dose proportionally, with moderate variability and minimal accumulation.

RESULTS

DOSE LEVELS EVALUATED

- Cohort 1: 120 mg ALG-010133 or placebo
- Cohort 2: 200 mg ALG-010133 or placebo
- Cohort 3: 400 mg ALG-010133 or placebo

BASELINE CHARACTERISTICS

The baseline characteristics were generally similar across treatment groups and typical for a VS CHB population.

PREDICTED EFFICACIOUS DOSE

200 to 400 mg QW SC dosing regimens were projected to be efficacious by maintaining ~1x EC50 in liver at Ctrough.

SAFETY

Administration of 120 mg, 200 mg, and 400 mg of ALG-010133 once weekly (QW) for 12 weeks was generally well tolerated:
• One unrelated SAE of orchitis (medical history of epididymo-orchitis)
• One TEAE (COVID-19 infection) leading to premature study drug discontinuation considered unrelated to study drug
• No clinically significant dose response in incidence of TEAEs.

CONCLUSIONS

• ALG-010133 was generally well tolerated with predictable PK properties when given to CHB subjects as 12 weekly SC doses of up to 400 mg.
• Compared to placebo, no meaningful HBsAg reduction was observed with all dose levels of ALG-010133 up to 400 mg.
• Further clinical development of ALG-010133 has been discontinued due to lack of efficacy.
• The reasons for lack of efficacy are currently unclear. Unfortunately, the high in vitro potency exhibited by ALG-010133 and the prior clinical efficacy data for compounds of a similar class (i.e., nucleic acid polymers) did not translate in this study to robust antiviral effects in CHB patients treated with ALG-010133. Notably, a reliable in vivo model to test compounds of this class is not currently available, reflective of a mechanism of action that is not fully understood.

ACKNOWLEDGEMENTS

The authors wish to thank the subjects for participating in this clinical study. The Sponsor is grateful to the staff of the clinical sites, the Aligos study teams, and to NovoNordisk for assisting in the conduct of the study.

REFERENCES

1 WHO HBV fact sheet 2021
3 Gane E et al. ILC 2021: Poster PO-1054.

CONTACT INFORMATION

Stanley Wang – swang@aligos.com